Antibody Dermatology Licensing Trials 
XTalks
APRIL 17, 2023
Monoclonal antibodies are gaining attention as alternative or additive treatments for atopic dermatitis. Lebrikizumab is a new and investigational monoclonal antibody designed to selectively inhibit IL-13. “In The safety of this trial was consistent with previously reported atopic dermatitis trials.
pharmaphorum
SEPTEMBER 30, 2022
Almirall has licensed an interleukin-2 (IL-2) drug from China’s Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases. It has also reached a deal with Ablexis to use its antibody development platform in therapeutics. Last year, Merck & Co paid $1.85
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 16, 2022
Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being. However, side effects do happen.
pharmaphorum
OCTOBER 1, 2021
Now, it says the drug has delivered “exciting” results in a proof-of-concept trial. Further details from the study – which involved four doses of either a high or low dose of the antibody over a 12-week period and a clinical assessment at 16 weeks – were presented at the EADV dermatology congress this week.
Drug Discovery World
SEPTEMBER 16, 2022
A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.
The Pharma Data
AUGUST 16, 2021
Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program – Safety profile consistent with prior lebrikizumab studies in atopic dermatitis. 1-4 The U.S. . Almirall S.A.’s
The Pharma Data
JUNE 7, 2022
The new findings from the Phase 3 clinical trials (ADvocate 1 and 2) showed eight out of ten patients who achieved clinical response (EASI-75*) with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with the once every two weeks or four weeks regimen. Almirall S.A.’s About Lebrikizumab.
Expert insights. Personalized for you.
97 
Let's personalize your content